Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Search
Search results
Could eye drops treat retinal disease in the future?
Researchers have developed PEDF-based eye drops that show promise in slowing retinal degeneration in mice with retinitis pigmentosa, potentially offering a non-invasive treatment option for preserving vision in the future.
Giving in memory
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
jCyte have released additional preclinical data regarding jCell
jCyte have released additional preclinical data regarding jCell
Podcast: Meet the professionals: Low vision specialist
In this episode, Lauren sits down with Louise Gow, a low vision specialist and the Head of Eye Health, Optometry and Low Vision at the RNIB.
Retina-on-a-chip: the tiny technology offering big hope for inherited sight loss
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
Meet our Trustee: Rob Halliwell
Rob is a Chief Technology Officer based in Manchester, with over 20 years’ experience leading technology, software development and digital transformation.
Looking after your vision
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Webinar: The Big Give: How your donations make a difference
Join us to find out how your donations make a direct different and fund research.
e-Newsletter October 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.